Oncopeptides AB (0RN4)
Market Closed
25 Jul, 15:30
LSE 
kr
6. 00
+1.01
+20.36%
kr
154.35M Market Cap
- P/E Ratio
0% Div Yield
39,800 Volume
0 Eps
kr 4.99
Previous Close Day Range
5.05 6.15
Year Range
1.29 6.15
Want to track 0RN4 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 22 days
Summary
0RN4 closed Friday higher at kr6, an increase of 20.36% from Thursday's close, completing a monthly increase of 304.86% or kr4.52. Over the past 12 months, 0RN4 stock gained 290.12%.
0RN4 is not paying dividends to its shareholders.
The last earnings report, released on May 08, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Aug 21, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
0RN4 Chart
Oncopeptides AB (0RN4) FAQ
What is the stock price today?
The current price is kr6.00.
On which exchange is it traded?
Oncopeptides AB is listed on XFRA.
What is its stock symbol?
The ticker symbol is 0RN4.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 154.35M.
When is the next earnings date?
The next earnings report will release on Aug 21, 2025.
Has Oncopeptides AB ever had a stock split?
No, there has never been a stock split.
Oncopeptides AB Profile
| Biotechnology Industry | Healthcare Sector | Dr. Jakob Lindberg Med. Lic CEO | LSE Exchange | SE0009414576 ISIN |
| Sweden Country | 63 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Oncopeptides AB (publ) stands out as a pioneering biotech entity, dedicated primarily to the commercialization, alongside the research and development of pioneering treatments aimed at combating hematological diseases, which are notoriously challenging to treat. The company showcases a global operational footprint, effectively extending its services across the United States, Europe, and other international markets. Established in the year 2000, Oncopeptides AB (publ) anchors its corporate headquarters in Stockholm, Sweden, marking a significant presence in the biotechnology sector, with a focused commitment towards addressing the unmet needs in the treatment of severe hematological conditions.
Products and Services
- Melflufen -- Melflufen represents the flagship product candidate from Oncopeptides AB (publ), designated specifically for the treatment of relapsed refractory multiple myeloma among adult patients. This particular therapeutic agent is distinguished as a drug conjugate, which underpins the company's innovative efforts in the complex field of oncology treatments. Melflufen's strategic development and proposed application underscore Oncopeptides AB's concentrated endeavor in advancing treatment options for multiple myeloma, a domain characterized by significant patient need.
Contact Information
Address: Vastra Tradgardsgatan 15
Phone: 46 86 15 20 40
Website: https://www.oncopeptides.com/sv
2025 © Marketlog. All Rights Reserved.
